NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Rebirthel Co., Ltd.

Rebirthel Co., Ltd.

Private
KyotoHealthcare & Life Scienceshttps://rebirthel.com/en/

Last Round

Series B

Dec 1, 2022

Total Funding Raised

$1.7M

Company Overview

Rebirthel Co., Ltd. is a biotechnology company that develops allogeneic T-cell immunotherapies using iPS cells to treat cancer and other immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapyallogeneic cell therapyiPS cell technologyoff-the-shelf therapyinduced pluripotent stem cellsiPSCcancer immunotherapybiotech licensingcell therapy platformoncology R&Doff-the-shelf CAR-Tuniversal CAR-Tnext-gen cell therapybiotech collaboration

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rebirthel Co., Ltd. Comparables

Compare Rebirthel Co., Ltd. with similar companies based on industry and business-model similarity.

Rebirthel Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shoreline Biosciences
83%
Cartherics
83%
Neukio Biotherapeutics
83%

Rebirthel Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 1, 2022
SeedMar 30, 2020

Key People

Founding team and executive leadership

Masunori Kajikawa

President And Chief Executive Officer

Executive Team

Rebirthel Co., Ltd. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 10, 2025

    Partnering with Eutilex to develop next-generation CAR-T therapies.

  • Mar 30, 2020

    Secured funding from Japan Science and Technology Agency.

Rebirthel Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rebirthel Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rebirthel Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersKyoto
Employee Range2
Year Founded2019
Last FundingDec 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.